NAD Sees Health Claims Without Clinical Trials As Risky But Possible
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Division intends its standards and reviews to be flexible but acknowledges it is “risky” for advertisers to support health claims without clinical trial RCT data, says senior attorney Kat Dunnigan.
You may also be interested in...
Nasacort 24HR Superiority Claims OK Without Head-To-Head Tests – NAD
“Strong scientific consensus with regard to product efficacy” justifies claims that Sanofi’s Nasacort Allergy 24HR is “the most effective OTC medicine for the treatment of nasal allergy symptoms,” NAD determines. Claritin-maker Merck, in its challenge, argued Sanofi needs head-to-head testing to support the claim.
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.
MoCRA Implementation In US Election Year: Q&A With Attorney Wade Ackerman
Wade Ackerman, partner at Covington & Burling who served previously as senior FDA counsel to US Senate Health Education, Labor & Pensions (HELP) Committee leadership, discusses expectations for FDA activity under modernized cosmetics regulations in 2024.